This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): VYSMN101 , VY SMN101
Description: VY-SMN101 is a gene replacement therapy targeting the survival motor neuron 1 (SMN1) gene.
Voyager and Sanofi
In February 2015, Voyager and Genzyme, a Sanofi company, announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. Genzyme will have the option to license several programs following completion of an initial proof-of-concept human clinical trial. However, Voyager will retain all U.S. rights to its lead product programs in Parkinsons disease (VY-AADC01) and Friedreichs ataxia (VY-FXN01). Voyager will split U.S. profits with Genzyme for the Huntingtons disease program (VY-HTT01). In addition, Voyagers lead amyotrophic lateral sclerosis (ALS) program (VY-SOD101) is not part of the collaboration and Voyager retains worldwide rights to this program.
The collaboration with Genzyme included an exclusive option to license, develop and commercialize worldwide rights to VY-SMN101. Genzyme's option for the Split Territory Programs and VY-SMN101 is triggered following the completion of the...See full deal structure in Biomedtracker
Additional information available to subscribers only: